Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps Latest publication
T cells
Cell-based therapy
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Jan/18/2023
Remdesivir
Cell-based therapy
Approved by FDA Experimental Antiviral Jan/18/2023
Mesenchymal stem cells
Cell-based therapy
Potential treatment - clinical evidence Experimental Other treatment Oct/17/2022
Convalescent plasma
Cell-based therapy
Emergency use authorization Experimental Antiviral May/16/2022
NK cells
Cell-based therapy
Potential treatment - theoretical effect Used to treat other disease Antiviral Dec/23/2021
Tocilizumab
Cell-based therapy
Recommended by China's NHC Guidelines Used to treat other disease Other treatment Dec/21/2021
Hematopoietic stem cells
Cell-based therapy
Potential treatment - clinical evidence Used to treat other disease Other treatment Oct/06/2021
LSNME/SW1
Cell-based therapy
Potential treatment - pre-clinical evidence Experimental Vaccine Oct/01/2021
rlcv-miR-rL1-28-3p
Cell-based therapy
Potential treatment - pre-clinical evidence Natural product Antiviral May/10/2021
aly-miR396a-5p
Cell-based therapy
Potential treatment - pre-clinical evidence Natural product Antiviral May/10/2021
ACE2-GpA-RBC
Cell-based therapy
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/10/2021
Menstrual blood-derived stem cells
Cell-based therapy
Potential treatment - clinical evidence Experimental Other treatment Mar/06/2021
NSC Ex/Mv
Cell-based therapy
Potential treatment - pre-clinical evidence Experimental Antiviral Dec/18/2020
Regdanvimab
Cell-based therapy
Authorized Experimental Antiviral